Swiss generic-drug and biosimilar maker spun off from Novartis, selling off-patent medicines worldwide.
Swiss generic-drug and biosimilar maker spun off from Novartis, selling off-patent medicines worldwide.
Sells off-patent medicines mainly to hospitals, pharmacies and health systems that buy by tender, so price and supply reliability win business; Europe is its largest region. Biosimilars, near copies of biotech drugs that have lost patent protection, are the growth line and include versions of Humira and denosumab.
In one line: A generics/biosimilars peer of Viatris.
Moat: narrow (scale, regulatory licence). Large manufacturing footprint and biosimilar approvals are costly to replicate, but products are largely undifferentiated.
Headquarters: Basel, Switzerland · Founded: 1886 · Employees: 23,000
Size Sandoz (SDZ.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $41.7B, the 14th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 81.50 on 18 Nov 2026.
Performance Over six months the shares gained 25.8%, against +16.9% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 0.8% over the last twelve months (peer median +14.0%); the operating margin is 15.2% (peer median 19.0%).
Valuation It trades at 24.5× forward earnings against a peer median of 17.9× (8th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.0 points above its cost of capital (5.0% WACC).
Credit Sandoz has 8 bonds outstanding ($4.66B), rated BBB by the agencies and trading like A- at a weighted spread of 100 bp.
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 9.21B | CHF 9.21B | CHF 9.12B | CHF 8.94B | CHF 8.86B |
| Revenue growth | — | +1% | +2% | +1% | — |
| Gross profit | CHF 4.38B | CHF 4.33B | CHF 4.31B | CHF 4.07B | CHF 4.15B |
| EBITDA | CHF 1.87B | CHF 1.81B | CHF 1.80B | CHF 1.57B | CHF 1.77B |
| Net income | CHF 515M | CHF 759M | CHF 0 | CHF 69.2M | CHF 810M |
| Free cash flow | CHF 1.08B | CHF 914M | CHF 222M | -CHF 1.80M | CHF 903M |
| Capital expenditure | CHF 762M | CHF 657M | CHF 526M | CHF 568M | CHF 408M |
| Total debt | n/a | CHF 4.50B | CHF 4.40B | CHF 3.84B | CHF 309M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Fresenius SE & Co. KGaA FRE.DE | $32.7B | +41% | +7% | 10% | 14.7× | 7.0% |
| Hikma Pharmaceuticals HIK.L | $4.58B | +15% | +2% | 20% | 9.8× | 2.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SDZ.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.7% | +5.7% | 11th highest of 21 |
| 6-month return | +25.8% | +16.9% | 7th highest of 21 |
| Distance from 52-week high | -6.2% | -8.7% | 9th highest of 21 |
| Revenue growth (TTM) | +0.8% | +14.0% | 3rd lowest of 21 |
| Operating margin | 15.2% | 19.0% | 6th lowest of 21 |
| Forward P/E | 24.5× | 17.9× | 8th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 7.5% | 8.4% | 7th least demanding of 18 |
| Growth delivered (Del g) | +0.4% | +8.9% | 2nd lowest of 18 |
| Hurdle (Req g minus delivered) | +7.1 pp | +0.2 pp | 7th most demanding of 18 |
| ROIC minus cost of capital | +5.0 pp | +4.4 pp | 10th highest of 21 |
| EV / EBITDA | 21.0× | 14.8× | 8th most expensive of 17 |
| Net debt / EBITDA | 2.1× | 0.7× | 6th most indebted of 17 |
| Bond spread | 100 bp | 88 bp | 3rd widest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | Hong Kong | $44.9B | -24% | +11% | 27% | 28.1× | 9.1% | +2.0% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Wuxi Apptec 2359.HK | Hong Kong | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% | +20.4% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Takeda Pharmaceutical 4502.T | Japan | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% | +7.1% |
| Merck KGaA MRK.DE | Germany | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% | +3.8% |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
Sandoz has 8 bonds outstanding with $4.66B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 3.77%, a spread of 100 bp over government bonds.